From: Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
All participants | Dementia (baseline) | No dementia (baseline) | Participants with follow-up data | |
---|---|---|---|---|
Number of subjects | 94 | 18 | 76 | 29 |
Age at baseline, years, mean ± SD (range) | 42.68 ± 14.87 (17–73) | 55.17 ± 9.92 (40–69) | 39.72 ± 14.34 (17–73) | 52.63 ± 8.88 (40–72) |
DS type | 89 (94.7%) trisomy, 2 (2.1%) translocation, 3 (3.2%) unknown | 18 (100.0%) trisomy | 71 (93.4%) trisomy, 2 (2.6%) translocation, 3 (3.9%) unknown | 28 (96.6%) trisomy, 1 (3.4%) unknown |
Sex | 41 (43.6%) female, 53 (56.4%) male | 6 (33.3%) female, 12 (66.7%) male | 35 (46.1%) female, 41 (55.9%) male | 10 (34.5%) female, 19 (65.5%) male |
Ethnicity | 85 (90.4%) white, 9 (9.6%) other | 17 (94.4.0%) white, 1 (5.6%) other | 68 (89.5%) white, 8 (10.5%) other | 27 (93.1%) white, 2 (6.8%) other |
Predementia ID level | 37 (39.4%) mild, 47 (50%) moderate, 9 (9.6%) severe, 1 (1.2%) unknown | 6 (33.3%) mild, 9 (50.0%) moderate, 3 (16.7%) severe | 31 (40.8%) mild, 38 (50%) moderate, 6 (7.9%) severe, 1 (1.3%) unknown | 13 (44.8%) mild, 12 (41.4%) moderate, 3 (10.3%) severe, 1 (3.4%) unknown |
APOE status | 68 (72.3%) non-APOE4 carrier, 23 (24.5%) APOE4 carrier, 3 (3.2%) unknown | 12 (66.7%) non-APOE4 carrier, 5 (27.8%) APOE4 carrier, 1 (5.5%) unknown | 56 (73.7%) non-APOE4 carrier, 18 (23.7%) APOE4 carrier, 2 (2.6%) unknown | 22 (75.9%) non-APOE4 carriers, 6 (20.7%) APOE4 carrier, 1 (3.4%) unknown |
NF-L level, ng/L, median (range) | 22.74 (6.11–136.91) | 63.76 (15.21–136.91) | 19.96 (6.11–116.84) | 32.67 (12.23–481.97) |